Burden of Insomnia and Sleep Disturbances and the Impact of Sleep Treatments in Patients with Probable or Possible Alzheimer’s Disease: A Structured Literature Review

por Benca, Ruth, Herring, W. Joseph, Khandker, Rezaul, Qureshi, Zaina P.
Publicado 2022

EE184 Assessing the Cost-Effectiveness of the Novavax COVID-19 Vaccine as a Potential Booster Vaccine Option for Adults in the United States

por Paret, K, Beyhaghi, H, Herring, W, Rousculp, M, Toback, S, Mauskopf, J
Publicado 2022

Pharmacokinetics of Sugammadex Dosed by Actual and Ideal Body Weight in Patients With Morbid Obesity Undergoing Surgery

por Mostoller, Kate, Wrishko, Rebecca, Maganti, Lata, Herring, W. Joseph, van Zutphen‐van Geffen, Mariëlle
Publicado 2020

Actual versus ideal body weight dosing of sugammadex in morbidly obese patients offers faster reversal of rocuronium- or vecuronium-induced deep or moderate neuromuscular block: a...

por Horrow, Jay C., Li, Wen, Blobner, Manfred, Lombard, John, Speek, Marcel, DeAngelis, Matthew, Herring, W. Joseph
Publicado 2021

Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial

por Herring, W. Joseph, Ceesay, Paulette, Snyder, Ellen, Bliwise, Donald, Budd, Kerry, Hutzelmann, Jill, Stevens, Joanne, Lines, Christopher, Michelson, David
Publicado 2020

A randomized trial evaluating the safety profile of sugammadex in high surgical risk ASA physical class 3 or 4 participants

por Herring, W. Joseph, Mukai, Yuki, Wang, Aobo, Lutkiewicz, Jeannine, Lombard, John F., Lin, Li, Watkins, Molly, Broussard, David M., Blobner, Manfred
Publicado 2021

A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia

por Connor, Kathryn M., Mahoney, Erin, Jackson, Saheeda, Hutzelmann, Jill, Zhao, Xin, Jia, Nan, Snyder, Ellen, Snavely, Duane, Michelson, David, Roth, Thomas, Herring, W. Joseph
Publicado 2016

Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder

por Connor, Kathryn M, Ceesay, Paulette, Hutzelmann, Jill, Snavely, Duane, Krystal, Andrew D, Trivedi, Madhukar H, Thase, Michael, Lines, Christopher, Herring, W Joseph, Michelson, David
Publicado 2017

Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man

por Gotter, Anthony L., Forman, Mark S., Harrell, Charles M., Stevens, Joanne, Svetnik, Vladimir, Yee, Ka Lai, Li, Xiaodong, Roecker, Anthony J., Fox, Steven V., Tannenbaum, Pamela L., Garson, Susan L., Lepeleire, Inge De, Calder, Nicole, Rosen, Laura, Struyk, Arie, Coleman, Paul J., Herring, W. Joseph, Renger, John J., Winrow, Christopher J.
Publicado 2016